Physician profile
Jeff Advincula
NPI 1063027514
$8,531.84
in general payments reported to CMS, 2019-2025
48 companies · $2,475 in 2025
The $2,475 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $1,138 · 2023: $1,531 · 2024: $2,417 · 2025: $2,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,422.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,134.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $987.06 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $824.33 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $786.86 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $586.58 | 2021-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $550.90 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.82 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $338.89 | 2021-2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $307.48 | 2024-2025 | Recorlev |
| Phathom Pharmaceuticals, INC. | $230.93 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $209.41 | 2021-2024 | Yupelri |
| Dexcom, INC. | $199.68 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $177.01 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $142.63 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $141.34 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Advincula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.